Caleb Rans

Contributing Writer https://www.cancertherapyadvisor.com

Caleb Rans is a clinical pharmacist and medical communications specialist with professional expertise in medical writing, editing, and contract clinical research. He holds a PharmD from the University of Alberta and presently resides in Vancouver, Canada. He currently works as an independent consultant for several news, CME, and pharmaceutical companies.

All articles by Caleb Rans

A group of doctors talking in a hospital.

General Oncology

Workplace Sexual Harassment: The Oncologist’s Experience

Caleb Rans

July 19, 2022

Survey results suggest that many oncologists experience sexual harassment in the workplace.

ASH 2021 Lymphoma In-depth

Parsaclisib Elicits ‘Rapid and Durable’ Responses in Relapsed/Refractory Follicular Lymphoma

Caleb Rans

December 17, 2021

The median duration of response was 14.7 months.

ASH 2021 Lymphoma In-depth

Tipifarnib Yields Responses in Relapsed/Refractory PTCL

Caleb Rans

December 17, 2021

The overall response rate was 56% in patients with angioimmunoblastic T-cell lymphoma.

ASH 2021 Lymphoma In-depth

Rates of ICANS, Steroid Use Higher With Axicabtagene Ciloleucel Than With Tisagenlecleucel

Caleb Rans

December 16, 2021

Axicabtagene ciloleucel was associated with higher rates of grade 3-5 ICANS and corticosteroid use.

ASH 2021 Lymphoma In-depth

Pembrolizumab Plus ICE: ‘Acceptable’ Salvage for Relapsed/Refractory Hodgkin Lymphoma

Caleb Rans

December 16, 2021

Pembrolizumab plus ICE chemotherapy was deemed “tolerable and efficacious.”

ASH 2021 Lymphoma In-depth

Romidepsin Plus CHOEP Falls Short in Newly Diagnosed Peripheral T-Cell Lymphoma

Caleb Rans

December 16, 2021

Adding romidepsin to CHOEP did not improve progression-free survival in transplant-eligible, newly diagnosed peripheral T-cell lymphoma.

ASH 2021 Lymphoma In-depth

Umbralisib Plus Ublituximab Shows Promise in Relapsed/Refractory Marginal Zone Lymphoma

Caleb Rans

December 16, 2021

Researchers sought to determine whether umbralisib plus ublituximab would be safe and active in patients with relapsed/refractory marginal zone lymphoma.